Sep 28, 2026 7:00 am EDT New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
Sep 24, 2026 4:30 pm EDT New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Sep 15, 2026 7:00 am EDT New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
Jul 22, 2026 7:00 am EDT Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Jul 14, 2026 4:30 pm EDT Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
